HK Stock MarketDetailed Quotes

02563 BIOSTAR PHARM-B

Watchlist
  • 28.950
  • -1.050-3.50%
Noon Break Dec 3 11:39 CST
10.55BMarket Cap-58603P/E (TTM)

BIOSTAR PHARM-B Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
Turnover
103.03%66.64M
73.71%56.61M
--32.82M
--32.59M
Operating income
103.03%66.64M
73.71%56.61M
32.82M
32.59M
Cost of sales
-121.59%-19.81M
-205.85%-18.03M
---8.94M
---5.89M
Operating expenses
-121.59%-19.81M
-205.85%-18.03M
-8.94M
-5.89M
Gross profit
96.08%46.83M
44.54%38.58M
23.88M
26.69M
Selling expenses
2.57%-95.4M
-19.54%-73.19M
---97.91M
---61.22M
Administrative expenses
14.76%-43.9M
21.97%-29.6M
---51.5M
---37.93M
Research and development expenses
-52.94%-126.54M
-110.40%-92.67M
---82.74M
---44.04M
Impairment and provision
206.03%1.28M
289.76%1.28M
---1.21M
---674K
-Other impairment is provision
206.03%1.28M
289.76%1.28M
---1.21M
---674K
Special items of operating profit
-42.62%28.14M
-33.17%25.44M
--49.04M
--38.07M
Operating profit
-18.17%-189.59M
-64.51%-130.15M
-160.44M
-79.11M
Financing cost
19.72%-57K
2.08%-47K
---71K
---48K
Earning before tax
-18.15%-189.64M
-64.47%-130.19M
-160.51M
-79.16M
After-tax profit from continuing operations
-18.15%-189.64M
-64.47%-130.19M
-160.51M
-79.16M
Earning after tax
-18.15%-189.64M
-64.47%-130.19M
-160.51M
-79.16M
Profit attributable to shareholders
-18.15%-189.64M
-64.47%-130.19M
-160.51M
-79.16M
Basic earnings per share
-17.39%-0.54
-60.87%-0.37
-0.46
-0.23
Diluted earnings per share
-17.39%-0.54
-60.87%-0.37
-0.46
-0.23
Currency Unit
CNY
CNY
CNY
CNY
Accounting Standards
HKAS
HKAS
HKAS
HKAS
Audit Opinions
Unqualified Opinion
--
Unqualified Opinion
--
Auditor
KPMG
--
KPMG
--
(FY)Dec 31, 2023 (Q9)Sep 30, 2023 (FY)Dec 31, 2022 (Q9)Sep 30, 2022
Turnover 103.03%66.64M 73.71%56.61M --32.82M --32.59M
Operating income 103.03%66.64M 73.71%56.61M 32.82M 32.59M
Cost of sales -121.59%-19.81M -205.85%-18.03M ---8.94M ---5.89M
Operating expenses -121.59%-19.81M -205.85%-18.03M -8.94M -5.89M
Gross profit 96.08%46.83M 44.54%38.58M 23.88M 26.69M
Selling expenses 2.57%-95.4M -19.54%-73.19M ---97.91M ---61.22M
Administrative expenses 14.76%-43.9M 21.97%-29.6M ---51.5M ---37.93M
Research and development expenses -52.94%-126.54M -110.40%-92.67M ---82.74M ---44.04M
Impairment and provision 206.03%1.28M 289.76%1.28M ---1.21M ---674K
-Other impairment is provision 206.03%1.28M 289.76%1.28M ---1.21M ---674K
Special items of operating profit -42.62%28.14M -33.17%25.44M --49.04M --38.07M
Operating profit -18.17%-189.59M -64.51%-130.15M -160.44M -79.11M
Financing cost 19.72%-57K 2.08%-47K ---71K ---48K
Earning before tax -18.15%-189.64M -64.47%-130.19M -160.51M -79.16M
After-tax profit from continuing operations -18.15%-189.64M -64.47%-130.19M -160.51M -79.16M
Earning after tax -18.15%-189.64M -64.47%-130.19M -160.51M -79.16M
Profit attributable to shareholders -18.15%-189.64M -64.47%-130.19M -160.51M -79.16M
Basic earnings per share -17.39%-0.54 -60.87%-0.37 -0.46 -0.23
Diluted earnings per share -17.39%-0.54 -60.87%-0.37 -0.46 -0.23
Currency Unit CNY CNY CNY CNY
Accounting Standards HKAS HKAS HKAS HKAS
Audit Opinions Unqualified Opinion -- Unqualified Opinion --
Auditor KPMG -- KPMG --

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data